Last reviewed · How we verify
S-amlodipine
At a glance
| Generic name | S-amlodipine |
|---|---|
| Also known as | Anydipine s |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients (PHASE3)
- Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B (PHASE1)
- Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
- An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)
- S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
- Analysis of Factors Influencing the Efficacy of Levamlodipine Benzoate and Its Population Pharmacodynamic Modeling
- Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Population Pharmacokinetic - Pharmacodynamic Models of Chronic Disease Therapeutics for Smokers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-amlodipine CI brief — competitive landscape report
- S-amlodipine updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI